IN2012DN00471A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00471A
IN2012DN00471A IN471DEN2012A IN2012DN00471A IN 2012DN00471 A IN2012DN00471 A IN 2012DN00471A IN 471DEN2012 A IN471DEN2012 A IN 471DEN2012A IN 2012DN00471 A IN2012DN00471 A IN 2012DN00471A
Authority
IN
India
Prior art keywords
compounds
pkm2
modulate
cancer
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Jeffrey O Saunders
Francesco O Salituro
Shunqi Yan
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43381412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00471(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IN2012DN00471A publication Critical patent/IN2012DN00471A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
IN471DEN2012 2009-06-29 2010-06-29 IN2012DN00471A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22143009P 2009-06-29 2009-06-29
US29236010P 2010-01-05 2010-01-05
PCT/US2010/040486 WO2011002817A1 (fr) 2009-06-29 2010-06-29 Composés et compositions thérapeutiques

Publications (1)

Publication Number Publication Date
IN2012DN00471A true IN2012DN00471A (fr) 2015-06-05

Family

ID=43381412

Family Applications (1)

Application Number Title Priority Date Filing Date
IN471DEN2012 IN2012DN00471A (fr) 2009-06-29 2010-06-29

Country Status (39)

Country Link
US (7) US8785450B2 (fr)
EP (3) EP2448582B1 (fr)
JP (2) JP5856052B2 (fr)
KR (2) KR101850813B1 (fr)
CN (2) CN104817498B (fr)
AR (1) AR077292A1 (fr)
AU (1) AU2010266386C1 (fr)
BR (1) BRPI1011587B1 (fr)
CA (2) CA2944788C (fr)
CL (1) CL2011003350A1 (fr)
CO (1) CO6480955A2 (fr)
CR (2) CR20170071A (fr)
CY (1) CY1119443T1 (fr)
DK (1) DK2448582T3 (fr)
EC (1) ECSP11011567A (fr)
ES (1) ES2632954T3 (fr)
FI (1) FIC20230017I1 (fr)
FR (1) FR23C1017I2 (fr)
HR (1) HRP20170955T1 (fr)
HU (2) HUE032969T2 (fr)
IL (1) IL217277A (fr)
IN (1) IN2012DN00471A (fr)
LT (2) LT2448582T (fr)
MX (1) MX2012000256A (fr)
MY (1) MY191825A (fr)
NI (1) NI201200003A (fr)
NL (1) NL301230I2 (fr)
NO (1) NO2023017I1 (fr)
NZ (2) NZ622505A (fr)
PE (1) PE20120693A1 (fr)
PL (1) PL2448582T3 (fr)
PT (1) PT2448582T (fr)
RU (1) RU2561132C2 (fr)
SG (3) SG177434A1 (fr)
SI (1) SI2448582T1 (fr)
TW (4) TWI472522B (fr)
UA (1) UA107667C2 (fr)
WO (1) WO2011002817A1 (fr)
ZA (1) ZA201200054B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
ES2619557T3 (es) 2009-05-04 2017-06-26 Agios Pharmaceuticals, Inc. Activadores de PKM2 para uso en el tratamiento del cáncer
PL2448581T3 (pl) 2009-06-29 2017-06-30 Agios Pharmaceuticals, Inc. Kompozycje terapeutyczne i odnośne sposoby ich stosowania
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
ES2812537T3 (es) 2009-10-21 2021-03-17 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
EP3064595B1 (fr) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
EP2509600B1 (fr) * 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2632920A1 (fr) 2010-10-27 2013-09-04 Dynamix Pharmaceuticals Ltd. Sulfonamides pour la modulation de pkm2
FR2967674B1 (fr) 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
CA2821975A1 (fr) 2010-12-17 2012-06-21 Shunqi Yan Derives de n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsufonamide comme modulateur de pyruvate kinase m2 pkm2
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
ES2569712T3 (es) 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. Activadores de PKM2 bicíclicos
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
WO2012151452A1 (fr) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc Activateurs de la pyruvate kinase destinés à une utilisation thérapeutique
US9181231B2 (en) 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
PT2704721T (pt) * 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9605521B2 (en) 2012-09-14 2017-03-28 Weatherford Technology Holdings, Llc Gas lift valve with mixed bellows and floating constant volume fluid chamber
JP6385352B2 (ja) 2012-10-15 2018-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
WO2014071512A1 (fr) * 2012-11-06 2014-05-15 Universite Laval Polythérapie et méthodes pour le traitement de maladies respiratoires
CN103808929A (zh) * 2012-11-08 2014-05-21 中国科学院上海生命科学研究院 一种gbss1比酶活测定方法
NZ707778A (en) * 2012-11-08 2019-03-29 Agios Pharmaceuticals Inc Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014139144A1 (fr) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
GB201419579D0 (en) * 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
WO2016115463A1 (fr) * 2015-01-15 2016-07-21 Whitehead Institute For Biomedical Research Inhibiteurs de phosphoglycérate déshydrogénase (phgdh) et utilisations associées
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
CN104803923B (zh) * 2015-04-22 2017-09-05 江苏恩华药业股份有限公司 一种1‑(2‑嘧啶)哌嗪盐酸盐的制备方法
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
WO2016201227A1 (fr) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Procédés d'utilisation d'activateurs de la pyruvate kinase
BR112018007671B1 (pt) 2015-10-15 2023-10-17 Les Laboratoires Servier Usos de um inibidor da idh1 e combinações
HRP20211790T1 (hr) 2015-10-15 2022-03-04 Les Laboratoires Servier Kombinirana terapija za liječenje maligniteta
MD3448859T2 (ro) 2017-03-20 2020-03-31 Forma Therapeutics Inc Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR)
BR112020003254A2 (pt) 2017-08-15 2020-10-27 Agios Pharmaceuticals, Inc. moduladores da piruvato quinase e uso destes
WO2019099651A1 (fr) * 2017-11-16 2019-05-23 Agios Pharmaceuticals, Inc. Procédés d'utilisation d'activateurs de pyruvate kinase deutérés
IL305343A (en) * 2017-11-22 2023-10-01 Agios Pharmaceuticals Inc Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
CN108440505A (zh) * 2018-03-30 2018-08-24 中南大学 依他匹隆的全合成方法
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
WO2020132459A1 (fr) * 2018-12-20 2020-06-25 The Regents Of The University Of Michigan Composés de quinolinyl-pyrazine-carboxamide et utilisations associées
WO2020167976A1 (fr) 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Dérivés thiéno[3,2-b]-pyrrole[3,2-d]pyridazinones et leur utilisation comme dérivés de pkm2 pour le traitement de troubles associés au cancer, à l'obésité et au diabète
MX2021014228A (es) * 2019-05-22 2022-02-21 Agios Pharmaceuticals Inc Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida.
US11878049B1 (en) * 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
EP4054583A4 (fr) * 2019-11-07 2023-10-25 Crinetics Pharmaceuticals, Inc. Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) et leurs utilisations
WO2021154987A1 (fr) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Formes à l'état solide de mitapivat et leur procédé de préparation
AU2021347349A1 (en) 2020-09-25 2023-06-08 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
KR20240004620A (ko) 2021-04-30 2024-01-11 아지오스 파마슈티컬스 아이엔씨. 미타피바트를 적정하는 방법
WO2023154036A1 (fr) 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Procédés de titrage de mitapivat
WO2022231627A1 (fr) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Procédés de titrage de mitapivat pour une utilisation dans le traitement de la thalassémie
CA3236880A1 (fr) 2021-11-16 2023-05-25 Agios Pharmaceuticals, Inc. Composes pour le traitement d'anemies associees au mds et d'autres affections
WO2024084501A1 (fr) 2022-10-17 2024-04-25 Mylan Laboratories Limited Polymorphes cristallins de mitapivat et d'hémisulfate de mitapivat
DE202022106287U1 (de) 2022-11-09 2022-11-21 Ahmad Salawi Eine Methode zur Synthese und biologischen Bewertung von neuen Sulfonamid-Analoga

Family Cites Families (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
NL76414C (fr) * 1949-07-23
GB935538A (en) * 1959-04-06 1963-08-28 Stop Motion Devices Corp Stop-motion head for use on knitting machines
GB1274436A (en) 1970-06-09 1972-05-17 Wolfen Filmfab Veb Process for the sensitization of photographic silver chloride and silver chlorobromide emulsions that may contain colour couplers
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
CH606334A5 (fr) 1974-06-21 1978-10-31 Ciba Geigy Ag
US3998828A (en) * 1975-01-31 1976-12-21 Pfizer Inc. 4-[2-(1,3-Dialkyl-1,2,3,4-tetra-hydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidine sulfonamide
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
DE2948434A1 (de) * 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
US4474599A (en) 1982-07-14 1984-10-02 The Dow Chemical Company 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8325370D0 (en) 1983-09-22 1983-10-26 Fujisawa Pharmaceutical Co Benzoxazoline and benzothiazoline derivatives
US4593102A (en) * 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
US4643759A (en) 1984-07-13 1987-02-17 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
IT1196195B (it) 1984-07-20 1988-11-10 Minnesota Mining & Mfg Copulanti formatori di colorante cian ed elementi e procedimenti fotografici
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
JPS61129129A (ja) 1984-11-28 1986-06-17 Kureha Chem Ind Co Ltd 抗腫瘍剤
FI855180A (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift.
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
EP0246749A3 (fr) * 1986-05-17 1988-08-31 AgrEvo UK Limited Triazoles herbicides
JPS6339875A (ja) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4775762A (en) * 1987-05-11 1988-10-04 The Dow Chemical Company Novel (1H-1,2,3-triazol-1-yl)pyridines
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
DE3813886A1 (de) 1988-04-20 1989-11-02 Schering Ag 1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
DE3813885A1 (de) 1988-04-20 1989-11-02 Schering Ag 1-chlorpyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
US5220028A (en) * 1988-10-27 1993-06-15 Nissan Chemical Industries, Ltd. Halogeno-4-methylpyrazoles
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DK0385237T3 (da) 1989-03-03 1994-07-25 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanopyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende dem
MY106533A (en) * 1990-02-20 1995-06-30 Sumitomo Chemical Co A 4-tert.-butyl imidazole derivative and its production and use.
CA2036148A1 (fr) * 1990-06-29 1991-12-30 Hiroki Tomioka Derive de 1-phenylimidazole ainsi que sa production et son utilisation
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
EP0565593B1 (fr) 1990-12-31 1999-03-03 Monsanto Company Reduction des interactions pesticides dans les recoltes
AU644297B2 (en) * 1991-06-28 1993-12-02 Sumitomo Chemical Company, Limited A 1-pyridylimidazole derivative and its production and use
IT1252567B (it) 1991-12-20 1995-06-19 Italfarmaco Spa Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi
WO1993017009A1 (fr) 1992-02-28 1993-09-02 Zenyaku Kogyo Kabushiki Kaisha DERIVE DE s-TRIAZINE ET REMEDE CONTRE DES MALADIES DEPENDENTES DE L'×STROGENE LE CONTENANT COMME INGREDIENT ACTIF
JPH0625177A (ja) 1992-07-09 1994-02-01 Nissan Chem Ind Ltd ピラゾール誘導体及び除草剤
JP3409165B2 (ja) * 1993-04-28 2003-05-26 株式会社林原生物化学研究所 養毛剤とその製造方法
JP3719612B2 (ja) 1993-06-14 2005-11-24 塩野義製薬株式会社 ヘテロ環を含有する尿素誘導体
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
CN1164232A (zh) * 1994-09-26 1997-11-05 曾尼卡有限公司 作为抗血栓形成剂或抗凝血剂的氨基杂环衍生物
RU2126001C1 (ru) * 1995-01-10 1999-02-10 Самдзин Фармасьютикал Ко., Лтд Производные пиперазина и фармацевтическая композиция на их основе
CA2210889C (fr) 1995-01-20 2007-08-28 G.D. Searle & Co. Inhibiteurs hydroxyethylamino contenant des bis-sulfinamides utilises pour inhiber des proteases retrovirales
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
WO1998021191A1 (fr) 1995-05-16 1998-05-22 Nissan Chemical Industries, Ltd. Derives de cyanoethylmelamine et procede de production
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
DE19541146A1 (de) 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
US6313127B1 (en) * 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0912519A1 (fr) * 1996-05-20 1999-05-06 Darwin Discovery Limited Sulfonamides de quinoline en tant qu'inhibiteurs de tnf et inhibiteurs de photodiesterase-iv
US5843485A (en) * 1996-06-28 1998-12-01 Incoe Corporation Valve-gate bushing for gas-assisted injection molding
AU3766897A (en) 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
DE19629335A1 (de) 1996-07-20 1998-01-22 Golden Records Ass Internation Karte aus Kunststoff
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
EP0970072A1 (fr) * 1997-03-11 2000-01-12 E.I. Dupont De Nemours And Company Herbicide d'heteroaryle azole
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
EP0986551B1 (fr) * 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Derives de la sulfonamide, leur production et leurs utilisations
JPH1158073A (ja) 1997-08-12 1999-03-02 Ishikawajima Harima Heavy Ind Co Ltd 吊ピース溶接装置
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
EP1042305B1 (fr) 1997-12-22 2005-06-08 Bayer Pharmaceuticals Corp. INHIBITION DE LA KINASE p38 PAR DES DIPHENYL-UREES SYMETRIQUES ET DISSYMETRIQUES
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6106849A (en) * 1998-01-21 2000-08-22 Dragoco Gerberding & Co. Ag Water soluble dry foam personal care product
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
JP2002523451A (ja) * 1998-09-01 2002-07-30 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル抑制剤および方法
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
CZ2001959A3 (cs) 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
US6211182B1 (en) 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
EP1187825A1 (fr) 1999-06-07 2002-03-20 Shire Biochem Inc. Inhibiteurs d'integrine thiophene
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
CA2382789A1 (fr) 1999-08-27 2001-03-08 Sugen, Inc. Mimetiques phosphates et procedes de traitement utilisant des inhibiteurs de phosphatase
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001019788A2 (fr) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US20010037689A1 (en) * 2000-03-08 2001-11-08 Krouth Terrance F. Hydraulic actuator piston measurement apparatus and method
US6515013B2 (en) 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
KR20030024799A (ko) 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
FR2817349B1 (fr) * 2000-11-28 2003-06-20 Centre Nat Rech Scient Nouveau procede de criblage de modulateurs de la transcription bacterienne
JP2002193710A (ja) 2000-12-25 2002-07-10 Kumiai Chem Ind Co Ltd ピリミジン又はトリアジン誘導体及び農園芸用殺菌剤
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
DE10164711A1 (de) 2001-03-13 2002-10-17 Schebo Biotech Ag Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen
US20030095958A1 (en) * 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
EP1387679A4 (fr) * 2001-05-07 2004-08-11 Smithkline Beecham Corp Sulfonamides
ATE404691T1 (de) * 2001-05-23 2008-08-15 Max Planck Gesellschaft Pyruvat-kinase als einem neuen zielmolekül
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
AU2002309435B2 (en) 2001-06-11 2008-08-14 Biovitrum Ab (Publ) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
JP4083397B2 (ja) * 2001-06-18 2008-04-30 株式会社ルネサステクノロジ 半導体集積回路装置
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
RU2283839C2 (ru) * 2001-08-15 2006-09-20 Е.И.Дюпон Де Немур Энд Компани Ортозамещенные ариламиды, способ борьбы с насекомыми, композиция для борьбы с насекомыми, промежуточное соединение
DK1423371T3 (da) 2001-08-17 2011-02-07 Basf Se Triazinderivater og anvendelse deraf som solbeskyttelse
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
JP2003081937A (ja) 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
WO2003037252A2 (fr) 2001-10-30 2003-05-08 Merck & Co., Inc. Inhibiteurs de tyrosines kinases
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
JP4216196B2 (ja) * 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
NZ534830A (en) 2002-03-13 2005-08-26 Janssen Pharmaceutica Nv Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases
EA007272B1 (ru) * 2002-03-13 2006-08-25 Янссен Фармацевтика Н. В. Новые ингибиторы гистондеацетилазы
US7452888B2 (en) * 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
CA2484209C (fr) 2002-05-03 2013-06-11 Exelixis, Inc. Modulateurs de proteine kinase et procedes d'utilisation
GB0215775D0 (en) 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
HUE029020T2 (en) 2002-07-18 2017-02-28 Janssen Pharmaceutica Nv Substituted triazine kinase inhibitors
JP4332112B2 (ja) 2002-08-09 2009-09-16 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
MXPA05004434A (es) 2002-10-24 2005-07-26 Sterix Ltd Inhibidores de 11-beta-hidroxi esteroide deshidrogenasa tipo 1 y tipo 2.
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
AU2003293333A1 (en) 2002-12-02 2004-06-23 Arqule, Inc. Method of treating cancers
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
JP2006515883A (ja) 2003-01-10 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド ２−デオキシグルコースによる癌の処置
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004089470A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique d'amides substitues
WO2004074438A2 (fr) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Antagonistes de ccr8
WO2004073619A2 (fr) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Antagonistes du recepteur ccr8
CN100361992C (zh) 2003-02-19 2008-01-16 霍夫曼-拉罗奇有限公司 用作pepck抑制剂的磺酰胺取代的黄嘌呤
WO2004076640A2 (fr) * 2003-02-25 2004-09-10 Ambion, Inc. Inhibiteurs d'angiogenine et de rnases a petites molecules et leurs procedes d'utilisation in vivo et in vitro
JP4969238B2 (ja) * 2003-03-27 2012-07-04 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CA2520546A1 (fr) * 2003-03-28 2005-02-10 Janssen Pharmaceutica, N.V. Composes benzo[1,2,5]thiadiazole
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
US6818631B1 (en) * 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
EP1689722A2 (fr) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation Derives de pyrimidine dans le traitement de troubles hyperproliferatifs
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
JP4099768B2 (ja) 2003-11-10 2008-06-11 富士電機デバイステクノロジー株式会社 電子写真感光体および該電子写真感光体に起因する干渉縞有無の判定方法
WO2005060956A1 (fr) 2003-12-12 2005-07-07 University Of Maryland, Baltimore Composes immunomodulateurs de ciblage et d'inhibition du site de liaison py+3 du domaine sh2 de la proteine p56 tyrosine kinase
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
RU2006122519A (ru) 2003-12-24 2008-01-27 Сайос, Инк. (Us) Лечение злокачественных глиом ингибиторами тфр-бэта
US20050170316A1 (en) 2004-01-29 2005-08-04 Russell Bruce M. Toothbrush for detecting the presence of plaque
US7585850B2 (en) * 2004-02-10 2009-09-08 Adenobio N.V. Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases
CA2556589A1 (fr) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. Derives de piperidine substitues en position 4
US7588779B2 (en) 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
GB0412526D0 (en) 2004-06-05 2004-07-14 Leuven K U Res & Dev Type 2 diabetes
EP1773310B9 (fr) * 2004-06-24 2012-04-25 Temple University - Of The Commonwealth System of Higher Education Sulfones, sulfoxydes, sulfonimides, sulfinimides, acylsulfonamides et acylsulfinamides alpha, beta-insatures et leurs utilisations therapeutiques
TW200606152A (en) 2004-07-02 2006-02-16 Tanabe Seiyaku Co Piperidine compound and process for preparing the same
FR2872704B1 (fr) * 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
RU2007110731A (ru) 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
WO2006033628A1 (fr) 2004-09-24 2006-03-30 Astrazeneca Ab Derives de benzimidazole, compositions les contenant et preparation et utilisation desdits derives
WO2006038594A1 (fr) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Inhibiteur de canal de calcium de type n
US20070249625A1 (en) 2004-10-20 2007-10-25 Jakob Busch-Petersen Il-8 Receptor Antagonists
US20080004269A1 (en) * 2004-11-04 2008-01-03 Yuelian Xu Pyrazolylmethy Heteroaryl Derivatives
SE0402762D0 (sv) 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
WO2006055880A2 (fr) * 2004-11-16 2006-05-26 Genzyme Corporation Procedes et compositions diagnostiques utilisant pkm2
WO2006063294A2 (fr) * 2004-12-09 2006-06-15 Kalypsys, Inc. Nouveaux inhibiteurs de l'histone deacetylase permettant de traiter une maladie
EP1836188A1 (fr) 2004-12-30 2007-09-26 Astex Therapeutics Limited Derives pyrazoliques modulant l'activite des kinases cdk, gsk et aurora
EP1844768A1 (fr) 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Dérivé de sulfone aromatique en tant que régulateur de récepteur de l'aldostérone
CA2594708A1 (fr) 2005-01-25 2006-08-03 Astrazeneca Ab Composes chimiques
UA94901C2 (ru) * 2005-02-18 2011-06-25 Астразенека Аб Антибактериальные производные пиперидина
SI1879877T1 (sl) 2005-05-03 2013-02-28 Ranbaxy Laboratories Limited Protimikrobna sredstva
EP1891028A1 (fr) 2005-05-18 2008-02-27 Forschungsverbund Berlin e.V. Inhibiteurs non peptidiques de l'interaction akap-pka
JP5904569B2 (ja) 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US20100105657A1 (en) * 2005-07-05 2010-04-29 Astrazeneca Ab Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease
WO2007008143A1 (fr) 2005-07-08 2007-01-18 Astrazeneca Ab Dérivés de sulfonamides hétérocycliques en tant qu'inhibiteurs du facteur xa
NZ565749A (en) * 2005-08-26 2010-12-24 Serono Lab Pyrazine derivatives and use as PI3K inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
FI20055644A0 (fi) * 2005-12-02 2005-12-02 Nokia Corp Ryhmäviestintä
US20090048227A1 (en) * 2005-12-22 2009-02-19 Chakravarty Pasun K Substituted-1-Phthalazinamines As Vr- 1 Antagonists
JP2009530231A (ja) 2006-01-20 2009-08-27 スミスクライン ビーチャム コーポレーション 代謝及び神経系の疾患の治療におけるスルホンアミド誘導体の使用
JP2007238458A (ja) 2006-03-06 2007-09-20 D Western Therapeutics Institute Inc 新規なイソキノリン誘導体及びこれを含有する医薬
JP2009533325A (ja) * 2006-03-17 2009-09-17 アストラゼネカ・アクチエボラーグ ５−ｈｔ６調節剤としての新規なテトラリン
AU2007231594A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008019139A2 (fr) 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibiteurs de la pyruvate kinase et procédés de traitement de maladie
US20090247499A1 (en) * 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
JP5068819B2 (ja) 2006-08-30 2012-11-07 メタノミクス ゲーエムベーハー 溶血性貧血を検査するための手段および方法
US7994094B2 (en) 2006-09-01 2011-08-09 Otsuka Agritechno Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent
WO2008043381A1 (fr) 2006-10-12 2008-04-17 Fluid Automation Systems S.A. Mécanisme de soupape culbutée et soupape culbutée
EP2074128B1 (fr) 2006-10-16 2013-08-14 Medicis Pharmaceutical Corporation Pyrazolyl thienopyridines therapeutiques
WO2008052190A2 (fr) 2006-10-26 2008-05-02 Flynn Gary A Modulateurs d'aquaporine et procédés pour leur utilisation pour le traitement d'un oedème et d'un déséquilibre de fluides
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
WO2008070661A1 (fr) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Pyrimidines substituées en tant qu'antagonistes des récepteurs de l'adénosine
RU2452484C2 (ru) 2006-12-08 2012-06-10 Милленниум Фармасьютикалз, Инк. Стандартные лекарственные препараты и способы лечения тромбоза пероральным введением ингибитора фактора ха
EP2425840B1 (fr) 2006-12-15 2015-04-08 Abraxis BioScience, Inc. Dérivés de triazine et leurs applications thérapeutiques
WO2008130718A1 (fr) * 2007-04-23 2008-10-30 Atherogenics, Inc. Composés contenant du sulfonamide pour le traitement de troubles inflammatoires
US8258295B2 (en) 2007-04-30 2012-09-04 Prometic Biosciences Inc. Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives
WO2008154026A1 (fr) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Composés pyrazole substitués
MX2010000690A (es) 2007-07-18 2010-06-25 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8.
CA2693901C (fr) 2007-07-20 2015-12-29 Nerviano Medical Sciences S.R.L. Derives d'indazole substitues actifs comme inhibiteurs de kinases
TW200906818A (en) 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
US8552050B2 (en) * 2007-08-16 2013-10-08 Beth Israel Deaconess Medical Center Activators of pyruvate kinase M2 and methods of treating disease
US20090163508A1 (en) 2007-10-10 2009-06-25 Takeda Pharmaceutical Company Limited Amide compound
EP2053045A1 (fr) 2007-10-26 2009-04-29 Syngenta Participations AG Nouveaux dérivés d'imidazole
KR20100101580A (ko) * 2007-10-26 2010-09-17 신젠타 파티서페이션즈 아게 신규한 이미다졸 유도체
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
WO2010007756A1 (fr) 2008-07-14 2010-01-21 塩野義製薬株式会社 Dérivé de pyridine ayant une activité d'inhibition de la ttk
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2010028179A1 (fr) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Composés hétérocycliques comme modulateurs de gata
MX359574B (es) 2008-09-03 2018-10-03 Univ Johns Hopkins Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
WO2010042867A2 (fr) 2008-10-09 2010-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activateurs de la pyruvate kinase humaine
WO2010059239A2 (fr) 2008-11-21 2010-05-27 Millennium Pharmaceuticals, Inc Sel de lactate du (4-isopropoxyphényl)-amide de l’acide 4-(6-méthoxy-7-(3-pipéridin-1-yl-propoxy)quinazolin-4-yl]pipérazine-1-carboxylique et les compositions pharmaceutiques l’incluant dans le traitement du cancer et d'autres pathologies ou troubles
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
ES2453474T3 (es) 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
ES2619557T3 (es) 2009-05-04 2017-06-26 Agios Pharmaceuticals, Inc. Activadores de PKM2 para uso en el tratamiento del cáncer
WO2010130638A1 (fr) 2009-05-14 2010-11-18 Evotec Ag Composés sulfamides, compositions pharmaceutiques et leurs utilisations
AU2010259002B2 (en) 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
WO2010144404A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Inhibiteurs pyridil-triazine de la signalisation hedgehog
WO2010144522A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Dérivés de la triazine substituée à l'uréidophényle et leurs applications thérapeutiques
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
PL2448581T3 (pl) 2009-06-29 2017-06-30 Agios Pharmaceuticals, Inc. Kompozycje terapeutyczne i odnośne sposoby ich stosowania
WO2011032169A2 (fr) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
EP3064595B1 (fr) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
ES2812537T3 (es) 2009-10-21 2021-03-17 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
EP2947073B1 (fr) 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Analogues cycliques fusionnés d'agents antifibrotiques
EP2509600B1 (fr) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
NZ601788A (en) 2010-03-01 2014-11-28 Myrexis Inc Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof
WO2011108724A1 (fr) * 2010-03-04 2011-09-09 味の素株式会社 Agent prophylactique ou thérapeutique pour le diabète ou l'obésité
EP2553116A4 (fr) 2010-04-01 2013-10-23 Agios Pharmaceuticals Inc Procédés d'identification d'un composé candidat
AU2011245441B2 (en) 2010-04-29 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2011153359A1 (fr) * 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Inhibiteurs du transporteur 1 de la glycine, procédés de fabrication associés, et utilisations associées
ES2704862T3 (es) 2010-07-16 2019-03-20 Agios Pharmaceuticals Inc Composiciones terapéuticamente activas y su método de uso
CA2849432A1 (fr) 2010-10-20 2012-04-26 Yota Devices Ipr Ltd Dispositif mobile
KR20210028747A (ko) 2010-10-21 2021-03-12 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
FR2967674B1 (fr) 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
US9351972B2 (en) 2010-11-29 2016-05-31 Galleon Pharmaceuticals, Inc. Compounds as respiratory stimulants for treatment of breathing control disorders or diseases
CA2821975A1 (fr) 2010-12-17 2012-06-21 Shunqi Yan Derives de n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsufonamide comme modulateur de pyruvate kinase m2 pkm2
ES2569712T3 (es) 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. Activadores de PKM2 bicíclicos
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
EP2671402B1 (fr) 2011-02-04 2017-01-18 Nec Corporation Système de radiocommunication, appareil de station de base, procédé de gestion des ressources radio et support lisible par ordinateur non transitoire
WO2012151452A1 (fr) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc Activateurs de la pyruvate kinase destinés à une utilisation thérapeutique
PT2704721T (pt) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US20140249150A1 (en) 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
SG10201602862RA (en) 2012-01-06 2016-05-30 Agios Pharmaceuticals Inc Therapeutically Active Compounds And Their Methods Of Use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JP6228130B2 (ja) 2012-01-19 2017-11-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびそれらの使用方法
EP2634259A1 (fr) 2012-03-01 2013-09-04 Deutsches Krebsforschungszentrum Supports et procédés pour la détermination du (D)-2-hydroxyglutarate (D2HG)
EP2824099A4 (fr) 2012-03-09 2015-11-11 Carna Biosciences Inc Nouveau dérivé de triazine
WO2014015422A1 (fr) 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Nanoparticules à base de cellulose pour administration de médicament
JP6385352B2 (ja) 2012-10-15 2018-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2016201227A1 (fr) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Procédés d'utilisation d'activateurs de la pyruvate kinase
IL305343A (en) * 2017-11-22 2023-10-01 Agios Pharmaceuticals Inc Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Also Published As

Publication number Publication date
LTPA2023513I1 (fr) 2023-05-25
LT2448582T (lt) 2017-07-10
TWI691493B (zh) 2020-04-21
PL2448582T3 (pl) 2017-09-29
CO6480955A2 (es) 2012-07-16
USRE49582E1 (en) 2023-07-18
US20190345109A1 (en) 2019-11-14
TWI598337B (zh) 2017-09-11
AR077292A1 (es) 2011-08-17
HRP20170955T1 (hr) 2017-11-17
EP3241554A1 (fr) 2017-11-08
KR20120107454A (ko) 2012-10-02
FR23C1017I1 (fr) 2023-06-23
EP3241554B1 (fr) 2020-01-29
CA2944788C (fr) 2023-08-22
NL301230I2 (nl) 2023-07-26
ECSP11011567A (es) 2012-02-29
TWI472522B (zh) 2015-02-11
SG10201403696UA (en) 2014-10-30
KR101850813B1 (ko) 2018-04-20
CN102481300B (zh) 2015-04-15
RU2012102922A (ru) 2013-08-10
JP5856052B2 (ja) 2016-02-09
KR101712035B1 (ko) 2017-03-03
EP2448582B1 (fr) 2017-04-19
AU2010266386B2 (en) 2016-06-23
CA2766882A1 (fr) 2011-01-06
US8785450B2 (en) 2014-07-22
CN102481300A (zh) 2012-05-30
TW201930288A (zh) 2019-08-01
BRPI1011587A2 (pt) 2016-03-22
CR20170071A (es) 2017-03-28
NI201200003A (es) 2012-11-12
TW201103913A (en) 2011-02-01
ES2632954T3 (es) 2017-09-18
US10029987B2 (en) 2018-07-24
SG177434A1 (en) 2012-02-28
MY191825A (en) 2022-07-18
ZA201200054B (en) 2013-10-30
IL217277A (en) 2016-06-30
NZ622505A (en) 2015-12-24
FIC20230017I1 (fi) 2023-05-02
PE20120693A1 (es) 2012-07-04
CA2944788A1 (fr) 2011-01-06
HUE032969T2 (en) 2017-11-28
HUS2300018I1 (hu) 2023-05-28
WO2011002817A1 (fr) 2011-01-06
US20100331307A1 (en) 2010-12-30
US20170183311A1 (en) 2017-06-29
IL217277A0 (en) 2012-02-29
CN104817498B (zh) 2018-06-01
US20140323467A1 (en) 2014-10-30
KR20170012585A (ko) 2017-02-02
TW201731828A (zh) 2017-09-16
FR23C1017I2 (fr) 2024-03-22
DK2448582T3 (en) 2017-07-17
NZ597379A (en) 2014-04-30
TW201520197A (zh) 2015-06-01
US20190241523A1 (en) 2019-08-08
JP2015028083A (ja) 2015-02-12
CL2011003350A1 (es) 2012-06-08
CA2766882C (fr) 2016-11-22
UA107667C2 (uk) 2015-02-10
EP2448582A4 (fr) 2012-11-28
US10988448B2 (en) 2021-04-27
BRPI1011587B1 (pt) 2020-03-24
TWI649313B (zh) 2019-02-01
EP2448582A1 (fr) 2012-05-09
MX2012000256A (es) 2012-04-19
JP2012532137A (ja) 2012-12-13
SG10201811480WA (en) 2019-01-30
CR20120001A (es) 2012-02-16
CN104817498A (zh) 2015-08-05
NO2023017I1 (no) 2023-04-27
US11866411B2 (en) 2024-01-09
US20210198206A1 (en) 2021-07-01
RU2561132C2 (ru) 2015-08-20
AU2010266386C1 (en) 2017-03-09
CY1119443T1 (el) 2018-03-07
PT2448582T (pt) 2017-07-10
EP3708169A1 (fr) 2020-09-16
SI2448582T1 (sl) 2017-09-29
AU2010266386A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
IN2012DN00471A (fr)
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
WO2010118063A3 (fr) Compositions thérapeutiques et procédés d'utilisation associés
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2013007268A (es) Activadores de pkm2 bicíclicos.
MX2011006290A (es) Compuestos de aza-azuleno.
MY184101A (en) Indoles
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
MX2011007930A (es) Conjugados de insulina cristalina.
MY160390A (en) Vinyl indazolyl compounds
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
IN2012DN03883A (fr)
MX2015012882A (es) Compuestos y composiciones terapeuticos.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IL207310A0 (en) Vaccine compositions
MX2009012233A (es) Compuestos de triazolil aminopirimidina.
MX2011006532A (es) Compuestos anticancerigenos.
MY159995A (en) Pyrimidinyl indole compounds
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer